Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00694850
Other study ID # 12916
Secondary ID 2023-507526-17-0
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 2, 2008
Est. completion date October 1, 2025

Study information

Verified date June 2024
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess multiple ascending doses of a new drug (BAY63-2521) given orally, to evaluate if it is safe and can help to improve the well-being, symptoms (e.g. disturbed breathing) and outcome of pulmonary hypertension associated with lung fibrosis. Patients living with pulmonary hypertension associated with interstitial lung disease have a risk of increased number of hospitalisations because of worsening of their condition. Until now there is no approved medication for this disease. The current treatment of pulmonary hypertension associated with interstitial lung disease consists: of oxygen and medical treatment with vasodilators, e.g. so-called Calcium-antagonists. Therefore, there is a need for new drugs in the treatment of pulmonary hypertension associated with interstitial lung disease.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 22
Est. completion date October 1, 2025
Est. primary completion date October 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of an interstitial lung disease (usual interstitial pneumonia [UIP], nonspecific interstitial pneumonia [NSIP] or sarcoidosis) with high resolution CT and a total lung capacity (TLC) = 90% or scleroderma associated pulmonary arterial hypertension (PAH) with total lung capacity (TLC) = 80%. - Interstitial lung disease (ILD) must have been stable for at least 3 months (decrease in forced vital capacity (FVC)< 10% and diffusing capacity of lung for carbon monoxide (DLco) < 15 % in 3 months), i.e. no significant changes in pulmonary function testing and stable medication in terms of ILD (e.g., corticosteroids, immunosuppressants) - Mean pulmonary vascular resistance (PVR) > 400 dyne sec cm-5 or mean pulmonary arterial pressure (PAP mean) > 30 mmHg - Pulmonary capillary wedge pressure (PCWP) < 15 mmHg - Hemodynamic parameters at baseline (PAP, PCWP, cardiac output [CO], systemic mean arterial pressure [SAP]) - High resolution computer tomography (HRCT) (should not be older than 12 months prior start of the study) - Heart rate > 55 beats per minute (BPM) and < 105 BPM at rest - Systolic blood pressure (SBP) > 90 mmHg - World Health Organisation (WHO) functional class II, III and IV - 6 Minute Walking Test (6MWT) > 100m and < 450 m - Stable controlled arterial hypertension according to current guidelines - Women of childbearing potential will be included in the study if the pregnancy test is negative and combination of condoms with a safe and highly effective contraception method (hormonal contraception with implants or combined oral contraceptives, certain intra-uterine devices [IUDs]) is granted. Exclusion Criteria: - Co-medication: - Patients pretreated with specific medication for pulmonary arterial hypertension (PAH) like endothelin receptor antagonists, prostaglandins or phosphodiesterase type 5 (PDE 5) blockers are excluded from the trial. - Requirement for concomitant use of nitrates are contraindicated. - Pre-existing clinically relevant lung disease other than ILD including. - Bronchial asthma and Chronic Obstructive Pulmonary Disease (COPD) with a forced expiratory volume in one second (FEV1)/FVC <60% pred., active tuberculosis - Pulmonary hypertension of another WHO group (I, II, IV and V) - Severe congenital abnormalities of the lungs, thorax and diaphragm - Clinical or radiological evidence of a pulmovenoocclusive disease (PVOD) - Systemic hemodynamics - Acute or severe chronic left heart failure (ejection fraction (EF) < 50%) - Severe coronary artery disease (CAD; EF < 50%); CAD patients must be asymptomatic and stable - Congenital or acquired valvular or myocardial disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension - Pulmonary function - TLC predicted < 30% - FEV1 (related to FVC) < 60% predicted - Blood gases at room air - Arterial partial carbon dioxide pressure (Pa CO2) > 45 mmHg - Arterial partial oxygen pressure (Pa O2) < 50 mmHg at O2 supply >/= 4 L/min - Peripheral organ function - Moderate or severe hepatic insufficiency (Child-Pugh Class Band C and/or total bilirubin > 2.5 mg/dl (0.043 mmol/L); and/or hepatic transaminases >3 upper limit normal [ULN]) - Moderate or severe renal insufficiency (creatinine > 2 mg/dl) or creatinine clearance according to Cockroft-Gault formula < 35 mL/ min

Study Design


Intervention

Drug:
Riociguat (Adempas, BAY63-2521)
BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Hoeper MM, Halank M, Wilkens H, Gunther A, Weimann G, Gebert I, Leuchte HH, Behr J. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013 Apr;41(4):853-60. doi: 10.1183/09031936.00213911. Epub 2012 Aug 30. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability 12 weeks treatment
Secondary Pharmacokinetics The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014 at every study visit except at run-in and Follow-up
Secondary 6-Minute Walk Test at every study visit except at Follow-up
Secondary Modified borg scale The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014 at every study visit except at Follow-up
Secondary Quality of life assessments The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014 at baseline, after 6 weeks, after 12 weeks, Follow-up and at each visit during long term extension phase
Secondary Hemodynamic parameters optional after 12weeks
Secondary Laboratory Parameters The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014 at each study visit during run-in and treatment phase and long term extension
Secondary Electrocardiogram (ECG) The assessment will be stopped after protocol amendment 4, which was effective since Jan 06, 2014 at each study visit during run-in and treatment phase and long term extension
Secondary Blood pressure and heart rate at each study visit during run-in and treatment phase and long term extension
See also
  Status Clinical Trial Phase
Completed NCT04095286 - Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants Phase 1
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT02191137 - Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Phase 4
Completed NCT01959828 - Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery Phase 3
Withdrawn NCT01202045 - Stress Echocardiography in the Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis Patients N/A
Completed NCT00963001 - Effect of Food on the Pharmacokinetics of Oral Treprostinil Phase 1
Completed NCT01121458 - Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed Phase 4
Completed NCT00963027 - Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil Phase 1
Terminated NCT00825266 - Insulin Resistance in Pulmonary Arterial Hypertension Phase 4
Terminated NCT00384865 - A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension Phase 2
Active, not recruiting NCT03926572 - Acute Decompensation of Pulmonary Hypertension N/A
Completed NCT02826252 - Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) N/A
Completed NCT02545465 - A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice N/A
Recruiting NCT04498299 - Stress Echocardiography in Patients Recovery From Mild COVID-19 Illness
Recruiting NCT02558582 - Effect of Exercise Training in Patients With Pulmonary Hypertension N/A
Active, not recruiting NCT02562235 - Riociguat in Children With Pulmonary Arterial Hypertension (PAH) Phase 3
Completed NCT02755298 - Chronic Clinical Effect of Acetazolamide Phase 2/Phase 3
Completed NCT02576002 - Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension) N/A
Terminated NCT03043976 - Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension N/A
Completed NCT01317134 - Endothelial Function in Patients With Pulmonary Arterial Hypertension N/A